Alzheimer’s disease is a type of dementia. Dementia can be defined as diseases affecting the brain and affecting the thinking ability of the patient. Other dementia diseases include Corticobasal degeneration, Creutzfeldt-Jakob disease, etc. these diseases are non curable diseases so far and a proper medicine is yet to be found. The peculiarity of dementia is that the disease becomes acute when ageing hence proper diagnosis of the disease is difficult.
The Alzheimer’s effect on each patient is different, even though a general symptom list has charted for the disease. The typical symptom of Alzheimer’s disease is the occurrence of short term memory loss. The stress related issues may also be taken seriously. The disease affects the thinking ability of the patient. When the disease advances to the final stages the symptoms include fluctuating mood, slow response and long term memory loss.
Alzheimer’s disease is a neurodegenerative type of disease more specifically, a disorder. The direct cause for this disease is still unknown. A systematic and successful treatment for the disease is yet to be found. Right now the medicine includes only detection of the disease.
The disease is of two stages:
Cognitive -It includes the mental state and ability of the patient like memory, judgment, reasoning, decision making, etc. A cognitive method is used to evaluate the mental state of the patient.
Functional impairments– It is a symptom which is because of nerve malfunctioning. When the functional impairment is discussed a diagnosis in physiological and psychological aspects are considered.
Alzheimer’s disease is a degenerative disease. It is not a curable disease the patient affected by his disease need assistance from others for survival. The patient loses the degree of language and speaking reduces to small phrases or words. Apathy is another peculiar symptom of this disease.
The diagnosis of the disease is based on the patient’s behavior and his history. The medical society has given systematic standards in diagnosing the reasoning ability and thinking of a patient to rate it as an Alzheimer’s disease or not. But by postmortem it can be clearly confirmed whether the patient had Alzheimer’s disease or not.
A group of scientists from Oxford University have discussed the importance of a new blood test that they have been experimenting. They claim that by identifying the behavior of 10 proteins in the blood, the symptoms of Alzheimer’s can be determined. The blood of the patient is tested, the content of these named proteins is analyzed and then a diagnosis about the onset of the disease can be concluded. In 2010 the fatality of the disease was about 40 million people and is believed to climb during the coming years. Countless experiments have been conducted on patients by the researchers all but failing. Simon Lovestone the researcher of Oxford University claims that the failure of all the experimented drugs for the Alzheimer’s disease is because of the acute condition of the patient. The drugs are experimented when the disease in the patients is in the most deadly phase, so that the drug doesn’t provide any chance of trial.
Johnson & Johnson, Eli Lilly, Roche, are some of the top research pharmaceuticals trying for an alternative drug for the disease.
Now a days, Positron emission tomography (PET) scan are used to determine the onset of the disease. The scan provides the symptoms of mild cognitive impairment. The problem is that they are expensive and common people hesitate to choose these tests.
The study conducted by the Oxford University under the leadership of Lovestone studied 1148 people 220 of them have mild cognitive impairment, 476 were affected by Alzheimer’s. The blood tests analyzed 25 proteins in the blood for the diagnosis of Alzheimer’s. Out of the total proteins 16 proteins have a strong connection to the symptoms of Alzheimer’s.
Even though the new blood test provides a strong fight against the disease, it doesn’t mean that right diagnosis has been found. The blood test has to undergo a lot more procedures and further studies to deeply analyze the quality of the new test and its diagnosing efficiency. After further diagnosis, a set of 10 proteins were listed which have a direct influence to the Alzheimer’s disease.